Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00121173 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00121173 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 16 participants.
The verdict
NCT00121173, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent cervical cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in preventing cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.
Interventions
- BIOLOGICAL pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-11 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00121173
The ClinicalTrials.gov registry entry for NCT00121173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is the first listed.
NCT00121173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00121173 about?
NCT00121173 is a clinical study titled "Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia". RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent cervical cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see ho...
What is the current status of trial NCT00121173?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2003-11. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00121173?
The interventions under investigation include: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00121173?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.